Shandong Weigao Group Medical Polymer Insiders Sold CN¥8.2m Of Shares Suggesting Hesitancy
Shandong Weigao Group Medical Polymer Insiders Sold CN¥8.2m Of Shares Suggesting Hesitancy
The fact that multiple Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period.
在過去的一年中,多位山東威高集團醫用高分子股份有限公司(HKG: 1066)內部人士拋售了大量股票,這一事實可能會引起投資者的關注。在評估內幕交易時,了解內部人士是否在買入通常更有幫助,因爲內幕賣出可能有多種解釋。但是,股東應更深入地研究是否有幾位內部人士在特定時間段內出售股票。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
雖然我們絕不會建議投資者僅根據公司董事的所作所爲做出決定,但邏輯要求你應該注意內部人士是在買入還是賣出股票。
See our latest analysis for Shandong Weigao Group Medical Polymer
查看我們對山東威高集團醫用聚合物的最新分析
Shandong Weigao Group Medical Polymer Insider Transactions Over The Last Year
山東威高集團醫用聚合物去年內幕交易
Over the last year, we can see that the biggest insider sale was by the Executive Chairman of the Board & Compliance Officer, Jing Long, for HK$5.8m worth of shares, at about HK$12.04 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is HK$7.68. So it is hard to draw any strong conclusion from it.
在過去的一年中,我們可以看到,最大的內幕出售是董事會執行主席兼合規官龍景龍,以每股約12.04港元的價格出售了價值580萬港元的股票。雖然我們通常不喜歡看到內幕拋售,但更令人擔憂的是銷售是否以較低的價格進行。令人欣慰的是,此次出售的價格遠高於目前的股價,即7.68港元。因此,很難從中得出任何有力的結論。
In the last year Shandong Weigao Group Medical Polymer insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
去年,山東威高集團醫用高分子內部人士沒有購買任何公司股票。你可以在下面看到過去 12 個月內幕交易(由公司和個人進行的)的直觀描述。如果你點擊圖表,你可以看到所有的個人交易,包括股價、個人和日期!
I will like Shandong Weigao Group Medical Polymer better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
如果我看到一些大規模的內幕買入,我會更喜歡山東威高集團醫用聚合物。在我們等待的同時,請查看這份免費名單,列出了最近有大量內幕買入的成長型公司。
Insider Ownership
內部所有權
Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 0.3% of Shandong Weigao Group Medical Polymer shares, worth about HK$90m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
許多投資者喜歡檢查公司有多少股份由內部人士擁有。我認爲,如果內部人士擁有該公司的大量股份,那將是一個好兆頭。業內人士擁有山東威高集團醫用聚合物0.3%的股份,價值約9000萬港元。儘管這是內部人所有權強勁但並不突出的水平,但這足以表明管理層與小股東之間有一定的一致性。
What Might The Insider Transactions At Shandong Weigao Group Medical Polymer Tell Us?
山東威高集團醫用聚合物的內幕交易可能告訴我們什麼?
There haven't been any insider transactions in the last three months -- that doesn't mean much. Still, the insider transactions at Shandong Weigao Group Medical Polymer in the last 12 months are not very heartening. The modest level of insider ownership is, at least, some comfort. Of course, the future is what matters most. So if you are interested in Shandong Weigao Group Medical Polymer, you should check out this free report on analyst forecasts for the company.
在過去的三個月中,沒有任何內幕交易——這並不意味着什麼。儘管如此,山東威高集團醫用高分子在過去12個月中的內幕交易並不令人鼓舞。內幕所有權的適度水平至少讓人感到安慰。當然,未來是最重要的。因此,如果你對山東威高集團醫用高分子感興趣,你應該看看這份關於該公司分析師預測的免費報告。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果你想看看另一家公司——一家財務狀況可能優越的公司——那麼千萬不要錯過這份免費的股本回報率高、債務低的有趣公司的名單。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。